263 related articles for article (PubMed ID: 8747407)
21. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.
Xiao ZS; Goldstein JA; Xie HG; Blaisdell J; Wang W; Jiang CH; Yan FX; He N; Huang SL; Xu ZH; Zhou HH
J Pharmacol Exp Ther; 1997 Apr; 281(1):604-9. PubMed ID: 9103550
[TBL] [Abstract][Full Text] [Related]
22. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
[TBL] [Abstract][Full Text] [Related]
23. Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population.
Xie HG; Huang SL; Xu ZH; Xiao ZS; He N; Zhou HH
Pharmacogenetics; 1997 Apr; 7(2):115-9. PubMed ID: 9170148
[TBL] [Abstract][Full Text] [Related]
24. 5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity.
Shu Y; Wang LS; Xu ZH; He N; Xiao WM; Wang W; Huang SL; Zhou HH
J Pharmacol Exp Ther; 2000 Nov; 295(2):844-51. PubMed ID: 11046127
[TBL] [Abstract][Full Text] [Related]
25. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation.
Brockmöller J; Rost KL; Gross D; Schenkel A; Roots I
Pharmacogenetics; 1995 Apr; 5(2):80-8. PubMed ID: 7663532
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects.
Katsuki H; Nakamura C; Arimori K; Fujiyama S; Nakano M
Eur J Clin Pharmacol; 1997; 52(5):391-6. PubMed ID: 9272410
[TBL] [Abstract][Full Text] [Related]
27. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population.
de Morais SM; Goldstein JA; Xie HG; Huang SL; Lu YQ; Xia H; Xiao ZS; Ile N; Zhou HH
Clin Pharmacol Ther; 1995 Oct; 58(4):404-11. PubMed ID: 7586932
[TBL] [Abstract][Full Text] [Related]
28. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.
Ibeanu GC; Goldstein JA; Meyer U; Benhamou S; Bouchardy C; Dayer P; Ghanayem BI; Blaisdell J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1490-5. PubMed ID: 9732415
[TBL] [Abstract][Full Text] [Related]
29. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population.
Kubota T; Chiba K; Ishizaki T
Clin Pharmacol Ther; 1996 Dec; 60(6):661-6. PubMed ID: 8988068
[TBL] [Abstract][Full Text] [Related]
30. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects.
Tybring G; Böttiger Y; Widén J; Bertilsson L
Clin Pharmacol Ther; 1997 Aug; 62(2):129-37. PubMed ID: 9284848
[TBL] [Abstract][Full Text] [Related]
31. The hydroxylation of omeprazole correlates with S-mephenytoin and proguanil metabolism.
Kortunay S; Basci NE; Bozkurt A; Isimer A; Sayal A; Kayaalp SO
Eur J Clin Pharmacol; 1997; 53(3-4):261-4. PubMed ID: 9476042
[TBL] [Abstract][Full Text] [Related]
32. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
[TBL] [Abstract][Full Text] [Related]
33. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population.
Sviri S; Shpizen S; Leitersdorf E; Levy M; Caraco Y
Clin Pharmacol Ther; 1999 Mar; 65(3):275-82. PubMed ID: 10096259
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects.
Ieiri I; Kubota T; Urae A; Kimura M; Wada Y; Mamiya K; Yoshioka S; Irie S; Amamoto T; Nakamura K; Nakano S; Higuchi S
Clin Pharmacol Ther; 1996 Jun; 59(6):647-53. PubMed ID: 8681489
[TBL] [Abstract][Full Text] [Related]
35. CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.
Sagar M; Seensalu R; Tybring G; Dahl ML; Bertilsson L
Scand J Gastroenterol; 1998 Oct; 33(10):1034-8. PubMed ID: 9829356
[TBL] [Abstract][Full Text] [Related]
36. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.
Ibeanu GC; Blaisdell J; Ghanayem BI; Beyeler C; Benhamou S; Bouchardy C; Wilkinson GR; Dayer P; Daly AK; Goldstein JA
Pharmacogenetics; 1998 Apr; 8(2):129-35. PubMed ID: 10022751
[TBL] [Abstract][Full Text] [Related]
37. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype.
Marinac JS; Balian JD; Foxworth JW; Willsie SK; Daus JC; Owen R; Flockhart DA
Clin Pharmacol Ther; 1996 Aug; 60(2):138-44. PubMed ID: 8823231
[TBL] [Abstract][Full Text] [Related]
38. Cyp2c19 genotype and omeprazole hydroxylation phenotype in Chinese Li population.
Wang JH; Li PQ; Fu QY; Li QX; Cai WW
Clin Exp Pharmacol Physiol; 2007; 34(5-6):421-4. PubMed ID: 17439410
[TBL] [Abstract][Full Text] [Related]
39. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
Rost KL; Brockmöller J; Esdorn F; Roots I
J Hepatol; 1995 Sep; 23(3):268-77. PubMed ID: 8550990
[TBL] [Abstract][Full Text] [Related]
40. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
